PT2266594E - Vegf para utilização no tratamento de distúrbios do sistema nervoso central - Google Patents
Vegf para utilização no tratamento de distúrbios do sistema nervoso central Download PDFInfo
- Publication number
- PT2266594E PT2266594E PT101791275T PT10179127T PT2266594E PT 2266594 E PT2266594 E PT 2266594E PT 101791275 T PT101791275 T PT 101791275T PT 10179127 T PT10179127 T PT 10179127T PT 2266594 E PT2266594 E PT 2266594E
- Authority
- PT
- Portugal
- Prior art keywords
- vegf
- treatment
- nervous system
- central nervous
- system disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/49—Platelet-derived growth factor [PDGF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/515—Angiogenesic factors; Angiogenin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Developmental Biology & Embryology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Vascular Medicine (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Ophthalmology & Optometry (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32338101P | 2001-09-19 | 2001-09-19 | |
US32604401P | 2001-09-28 | 2001-09-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT2266594E true PT2266594E (pt) | 2015-08-05 |
Family
ID=26983933
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT101791275T PT2266594E (pt) | 2001-09-19 | 2002-09-19 | Vegf para utilização no tratamento de distúrbios do sistema nervoso central |
PT2798797T PT1443955E (pt) | 2001-09-19 | 2002-09-19 | Pdgf-bb para o tratamento da doença de parkinson |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT2798797T PT1443955E (pt) | 2001-09-19 | 2002-09-19 | Pdgf-bb para o tratamento da doença de parkinson |
Country Status (10)
Country | Link |
---|---|
US (2) | US7981863B2 (pt) |
EP (3) | EP1443955B1 (pt) |
AU (1) | AU2002334327B2 (pt) |
CA (1) | CA2461176C (pt) |
CY (1) | CY1113699T1 (pt) |
DK (2) | DK1443955T3 (pt) |
ES (2) | ES2546093T3 (pt) |
HK (2) | HK1152243A1 (pt) |
PT (2) | PT2266594E (pt) |
WO (1) | WO2003024478A1 (pt) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9694038B2 (en) * | 2000-04-06 | 2017-07-04 | Wayne P. Franco | Combination growth factor therapy and cell therapy for treatment of acute and chronic diseases of the organs |
US20050232921A1 (en) * | 2001-04-13 | 2005-10-20 | Rosen Craig A | Vascular endothelial growth factor 2 |
DK1385864T3 (da) * | 2001-04-13 | 2010-08-16 | Human Genome Sciences Inc | Anti-VEGF-2-antistoffer |
WO2002083849A2 (en) * | 2001-04-13 | 2002-10-24 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
US7943376B2 (en) * | 2001-04-27 | 2011-05-17 | Stem Cell Therapuetics Inc. | Platelet derived growth factor (PDGF)-derived neurospheres define a novel class of progenitor cells |
US20040214766A1 (en) * | 2001-10-01 | 2004-10-28 | Kari Alitalo | VEGF-C or VEGF-D materials and methods for treatment of neuropathologies |
AU2003213078A1 (en) * | 2002-02-14 | 2003-09-04 | Buck Institute | Neurogenerative or neurotrophic factors for mitigating a symptom of ischemia |
GB0205772D0 (en) * | 2002-03-12 | 2002-04-24 | Gill Steven S | Catheter |
WO2003094965A2 (en) * | 2002-05-08 | 2003-11-20 | Neuronova Ab | Modulation of neural stem cells with s1p or lpa receptor agonists |
WO2005030240A2 (en) * | 2003-09-23 | 2005-04-07 | Ludwig Institute For Cancer Research | Vege-cor vege-d materials and methods for stimulation of neural stem cells |
WO2004093802A2 (en) * | 2003-04-17 | 2004-11-04 | The Board Of Trustees Of The Leland Stanford Junior University | Prevention of deficits in neurogenesis with anti-inflammatory agents |
US7998460B2 (en) * | 2003-04-17 | 2011-08-16 | The Board Of Trustees Of The Leland Stanford Junior University | Prevention of deficits in neurogenesis with anti-inflammatory agents |
JP4861177B2 (ja) * | 2003-09-12 | 2012-01-25 | ニューロノバ エービー | 神経系の障害の処置 |
US20070269412A1 (en) | 2003-12-02 | 2007-11-22 | Celavie Biosciences, Llc | Pluripotent cells |
US20080118480A1 (en) * | 2003-12-19 | 2008-05-22 | Imclone Systems Incorporated | Methods and Compositions for Directing Migration of Neural Progenitor Cells |
AU2005222902B2 (en) * | 2004-03-12 | 2010-06-10 | Alnylam Pharmaceuticals, Inc. | iRNA agents targeting VEGF |
SI1755647T1 (sl) * | 2004-05-27 | 2011-01-31 | Vib Vzw | Zdravljenje amiotrofiäśne lateralne skleroze |
WO2006055743A2 (en) * | 2004-11-18 | 2006-05-26 | Franco, Wayne | Compbination growth therapy and cell therapy for treatment of acute and chronic diseases of the organs |
WO2006059777A1 (ja) * | 2004-11-30 | 2006-06-08 | Angesmg, Inc. | アルツハイマー治療剤 |
EP1831354A4 (en) * | 2004-12-01 | 2008-01-23 | Stem Cell Therapeutics Corp | NEURAL PRECURSOR CELLS SENSITIVE TO PLATELET GROWTH FACTOR AND PROHIBITION OF SAID CELLS |
KR101547579B1 (ko) * | 2006-03-31 | 2015-08-27 | 알닐람 파마슈티칼스 인코포레이티드 | Eg5 유전자의 발현을 억제하는 이본쇄 리보핵산 |
WO2007124308A2 (en) * | 2006-04-17 | 2007-11-01 | Ludwig Institute For Cancer Research | Methods and compositions for modulation of blood-neural barrier |
US8598333B2 (en) * | 2006-05-26 | 2013-12-03 | Alnylam Pharmaceuticals, Inc. | SiRNA silencing of genes expressed in cancer |
US20080044847A1 (en) | 2006-06-23 | 2008-02-21 | Shusta Eric V | Blood-Brain Barrier Model |
CN100445373C (zh) * | 2006-12-04 | 2008-12-24 | 山东大学 | 黄樟素氧化物在内皮细胞与神经干细胞培养体系中的应用 |
DE102007019162A1 (de) * | 2007-04-20 | 2008-10-23 | Johann Wolfgang Goethe-Universität Frankfurt am Main | Verwendung von EGFL7 zur Modulation von Zellen |
KR101397407B1 (ko) * | 2008-03-05 | 2014-06-19 | 알닐람 파마슈티칼스 인코포레이티드 | Eg5 및 VEGF 유전자의 발현을 억제하기 위한 조성물 및 방법 |
ES2376930B1 (es) * | 2009-02-05 | 2013-01-24 | Universidad Del Pais Vasco | Método para el tratamiento de enfermedades neurodegenerativas. |
US20100209399A1 (en) * | 2009-02-13 | 2010-08-19 | Celavie Biosciences, Llc | Brain-derived stem cells for repair of musculoskeletal system in vertebrate subjects |
CN102448472A (zh) | 2009-05-25 | 2012-05-09 | 国立大学法人东京工业大学 | 包含与中枢神经细胞的增殖和分化相关的核因子的药物组合物 |
KR20140024914A (ko) | 2011-04-29 | 2014-03-03 | 셀진 코포레이션 | 예측인자로 세레브론을 사용하는 암 및 염증성 질환의 치료를 위한 방법 |
WO2012163542A1 (en) * | 2011-06-01 | 2012-12-06 | Universität Heidelberg | Vegf-d/vegfr2/3-mediated regulation of dendrites |
EP2529745A1 (en) * | 2011-06-01 | 2012-12-05 | Universität Heidelberg | VEGF-D/VEGFR mediated regulation of dendrites |
US9415090B2 (en) | 2011-06-01 | 2016-08-16 | Universität Heidelberg | VEGF-D/VEGFR2/3-mediated regulation of dendrites |
ES2699810T3 (es) | 2012-06-29 | 2019-02-12 | Celgene Corp | Métodos para determinar la eficacia de fármacos usando proteínas asociadas a cereblon |
US9587281B2 (en) | 2012-08-14 | 2017-03-07 | Celgene Corporation | Cereblon isoforms and their use as biomarkers for therapeutic treatment |
RU2542385C2 (ru) * | 2012-08-31 | 2015-02-20 | Общество с ограниченной ответственностью "НекстГен" | Способ получения фармацевтической композиции для индукции развития кровеносных сосудов в тканях, фармацевтическая композиция, полученная этим способом, и способ лечения ишемии тканей и/или органов человека |
WO2015089049A1 (en) * | 2013-12-09 | 2015-06-18 | Thomas Jefferson University | Novel methods of treating a neurodegenerative disease in a mammal in need thereof |
US10369329B2 (en) | 2014-01-30 | 2019-08-06 | Renishaw Plc | Neurosurgical apparatus and method |
US10272117B2 (en) | 2014-02-24 | 2019-04-30 | Celgene Corporation | Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders |
KR102248804B1 (ko) * | 2014-03-12 | 2021-05-11 | 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 | Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소 |
JP6640126B2 (ja) | 2014-06-27 | 2020-02-05 | セルジーン コーポレイション | セレブロン及び他のe3ユビキチンリガーゼの立体構造の変化を誘導するための組成物及び方法 |
WO2016092453A1 (en) * | 2014-12-07 | 2016-06-16 | Ramot At Tel-Aviv University Ltd. | Prevention or reversal of apoe4 induced brain pathology by activation of vegf receptors |
GB201506052D0 (en) | 2015-04-09 | 2015-05-27 | Renishaw Plc | Movement disorder |
RU2612497C2 (ru) | 2015-05-26 | 2017-03-09 | Общество с ограниченной ответственностью "НекстГен" | Оптимизированная нуклеотидная последовательность и фармацевтическая композиция на ее основе с пролонгированной экспрессией трансгена vegf |
WO2017117118A1 (en) | 2015-12-28 | 2017-07-06 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases |
EP3412296A4 (en) * | 2016-02-05 | 2019-09-11 | Kyungpook National University Industry-Academic Cooperation Foundation | PHARMACEUTICAL COMPOSITION COMPRISING STEM CELLS IN WHICH A VASCULAR ENDOTHELIUM GROWTH FACTOR IS OVEREXPRESSED AS AN ACTIVE INGREDIENT TO PREVENT OR TREAT NEURODEGENERATIVE DISEASE |
RU2639175C1 (ru) * | 2016-11-14 | 2017-12-20 | Общество с ограниченной ответственностью "НекстГен" | Способ индукции регенерации периферического нерва |
US20230033523A1 (en) * | 2021-07-30 | 2023-02-02 | The Research Foundation For The State University Of New York | Method of treating cerebral autosomal dominant arteriopathy with subcortical infarct and leukoencephalopathy (cadasil) |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4692147A (en) | 1980-04-02 | 1987-09-08 | Medtronic, Inc. | Drug administration device |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5219759A (en) | 1987-04-22 | 1993-06-15 | Chiron Corporation | Recombinant DNA encoding PDGF A-chain polypeptide and expression vectors |
US4899919A (en) | 1988-04-01 | 1990-02-13 | Clumb Thomas E | Self energizing fastener system |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
IT1237435B (it) | 1989-12-14 | 1993-06-04 | Farmaco attivo nel ripristino della plasticita' neuronale. | |
DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US6497872B1 (en) | 1991-07-08 | 2002-12-24 | Neurospheres Holdings Ltd. | Neural transplantation using proliferated multipotent neural stem cells and their progeny |
US6071889A (en) * | 1991-07-08 | 2000-06-06 | Neurospheres Holdings Ltd. | In vivo genetic modification of growth factor-responsive neural precursor cells |
US5980885A (en) * | 1991-07-08 | 1999-11-09 | Neurospheres Holdings Ltd. | Growth factor-induced proliferation of neural precursor cells in vivo |
US6294346B1 (en) * | 1991-07-08 | 2001-09-25 | Neurospheres Holdings, Ltd. | Use of multipotent neural stem cells and their progeny for the screening of drugs and other biological agents |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
WO1993010806A1 (en) | 1991-11-25 | 1993-06-10 | Institute Of Molecular Biology, Inc. | Medicament for promoting growth of mammalian nerve |
JPH07509137A (ja) | 1992-07-24 | 1995-10-12 | セル ジェネシス,インク. | 異種抗体の生産 |
DE69430824T2 (de) * | 1993-08-12 | 2003-01-23 | Neurotech Sa | Biokompatible immunoisolatorische Kapseln, die genetisch veränderte Zellen enthalten |
SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
US6040157A (en) | 1994-03-08 | 2000-03-21 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
NZ301611A (en) * | 1995-03-02 | 2000-02-28 | Amrad Operations Pty Ltd | a peptide having vascular endothelial growth factor like properties, nucleic acid molecule encoding it and its use |
US5670477A (en) | 1995-04-20 | 1997-09-23 | Joseph F. Poduslo | Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents |
KR20050085971A (ko) | 1995-04-27 | 2005-08-29 | 아브게닉스, 인크. | 면역화된 제노마우스 유래의 인간 항체 |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5711316A (en) | 1996-04-30 | 1998-01-27 | Medtronic, Inc. | Method of treating movement disorders by brain infusion |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
US6042579A (en) | 1997-04-30 | 2000-03-28 | Medtronic, Inc. | Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain |
US6455283B1 (en) | 1998-03-17 | 2002-09-24 | Genentech, Inc. | Nucleic acids encoding vascular endothelial cell growth factor-E (VEGF-E) |
US6165783A (en) | 1997-10-24 | 2000-12-26 | Neuro Spheres Holdings Ltd. | Erythropoietin-mediated neurogenesis |
EP1060242A4 (en) | 1998-01-23 | 2003-09-17 | Imclone Systems Inc | PURIFIED POPULATIONS OF STEM CELLS |
US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
ES2216630T3 (es) * | 1998-09-09 | 2004-10-16 | Scios Inc | Metodos de tratar la hipertension dependiente de la sal. |
US6432673B1 (en) * | 1998-12-07 | 2002-08-13 | Zymogenetics, Inc. | Growth factor homolog ZVEGF3 |
EP1187843A1 (en) * | 1999-06-03 | 2002-03-20 | Human Genome Sciences, Inc. | Angiogenic proteins and uses thereof |
EP1210106A2 (en) | 1999-08-18 | 2002-06-05 | The General Hospital Corporation | Methods, compositions and kits for promoting recovery from damage to the central nervous system |
WO2001021214A1 (fr) | 1999-09-21 | 2001-03-29 | Medgene Bioscience, Inc. | Thérapie génique pour troubles cérébro-vasculaires |
AU2631001A (en) | 2000-01-05 | 2001-07-16 | Zymogenetics Inc. | Novel fgf homolog zfgf11 |
US7582292B2 (en) * | 2000-02-26 | 2009-09-01 | Artecel, Inc. | Adipose tissue derived stromal cells for the treatment of neurological disorders |
EP2295070B1 (en) | 2000-04-12 | 2015-08-12 | Vib Vzw | Use of VEGF and homologues to treat neuron disorders |
US7943376B2 (en) | 2001-04-27 | 2011-05-17 | Stem Cell Therapuetics Inc. | Platelet derived growth factor (PDGF)-derived neurospheres define a novel class of progenitor cells |
US20040214766A1 (en) * | 2001-10-01 | 2004-10-28 | Kari Alitalo | VEGF-C or VEGF-D materials and methods for treatment of neuropathologies |
WO2005016963A2 (en) * | 2003-06-12 | 2005-02-24 | Ludwig Institute For Cancer Research | Heparin binding veger-3 ligands |
DK2548578T3 (da) * | 2006-05-17 | 2014-10-06 | Ludwig Inst Cancer Res | Målretning af VEGF-B-regulering af fedtsyretransportører til modulering af humane sygdomme |
WO2008066630A2 (en) * | 2006-10-27 | 2008-06-05 | Caritas St. Elizabeth Medical Center Of Boston, Inc. | Methods for reprogramming adult somatic cells and uses thereof |
-
2002
- 2002-09-18 US US10/246,091 patent/US7981863B2/en not_active Expired - Fee Related
- 2002-09-19 ES ES10179127.5T patent/ES2546093T3/es not_active Expired - Lifetime
- 2002-09-19 PT PT101791275T patent/PT2266594E/pt unknown
- 2002-09-19 AU AU2002334327A patent/AU2002334327B2/en not_active Ceased
- 2002-09-19 EP EP02798797A patent/EP1443955B1/en not_active Expired - Lifetime
- 2002-09-19 PT PT2798797T patent/PT1443955E/pt unknown
- 2002-09-19 EP EP10179127.5A patent/EP2266594B1/en not_active Expired - Lifetime
- 2002-09-19 ES ES02798797T patent/ES2396545T3/es not_active Expired - Lifetime
- 2002-09-19 WO PCT/IB2002/003998 patent/WO2003024478A1/en not_active Application Discontinuation
- 2002-09-19 CA CA2461176A patent/CA2461176C/en not_active Expired - Fee Related
- 2002-09-19 DK DK02798797.3T patent/DK1443955T3/da active
- 2002-09-19 EP EP10179119A patent/EP2289537A1/en not_active Withdrawn
- 2002-09-19 DK DK10179127.5T patent/DK2266594T3/en active
-
2005
- 2005-02-12 HK HK11106377.7A patent/HK1152243A1/xx not_active IP Right Cessation
- 2005-02-12 HK HK05101145.7A patent/HK1068501A1/xx not_active IP Right Cessation
-
2011
- 2011-06-14 US US13/159,623 patent/US20120077741A1/en not_active Abandoned
-
2012
- 2012-12-12 CY CY20121101218T patent/CY1113699T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
ES2546093T3 (es) | 2015-09-18 |
CY1113699T1 (el) | 2016-06-22 |
EP1443955A1 (en) | 2004-08-11 |
EP2289537A1 (en) | 2011-03-02 |
AU2002334327B2 (en) | 2006-05-04 |
HK1068501A1 (en) | 2005-04-22 |
PT1443955E (pt) | 2012-12-26 |
DK2266594T3 (en) | 2015-08-10 |
WO2003024478A9 (en) | 2003-06-05 |
DK1443955T3 (da) | 2013-01-02 |
EP1443955B1 (en) | 2012-09-12 |
ES2396545T3 (es) | 2013-02-22 |
US20030203844A1 (en) | 2003-10-30 |
WO2003024478A1 (en) | 2003-03-27 |
EP2266594B1 (en) | 2015-05-27 |
CA2461176C (en) | 2013-11-05 |
US7981863B2 (en) | 2011-07-19 |
EP2266594A1 (en) | 2010-12-29 |
US20120077741A1 (en) | 2012-03-29 |
HK1152243A1 (en) | 2012-02-24 |
CA2461176A1 (en) | 2003-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1152243A1 (en) | Vegf for use in the treatment of central nervous system disorders vegf | |
PL373626A1 (en) | Treatment for central nervous system disorders | |
HK1092367A1 (en) | Combination therapy for the treatment of ocular neovascular disorders | |
IL175055A0 (en) | Combinations useful for the treatment of neuronal disorders | |
AU2003249983A8 (en) | Piperidines useful for the treatment of central nervous system disorders | |
IL159771A0 (en) | Combinations for the treatment of inflammatory disorders | |
AU9112201A (en) | Pulmonary delivery in treating disorders of the central nervous system | |
IL160389A0 (en) | Use of flibanserin for the treatment of sexual disorders | |
PL378108A1 (pl) | Leczenie łączone do terapii zapalnych zaburzeń immunologicznych | |
PL372425A1 (en) | Dihydrobenzodiazepin-2-one-derivatives for the treatment of neurological disorders | |
IL176581A0 (en) | Immunomodulatory compounds for the treatment of central nervous system disorders | |
GB0007193D0 (en) | Treatment of movrmrnt disorders | |
IL161267A0 (en) | Combinations for the treatment of immunoinflammatory disorders | |
IL155589A0 (en) | Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders | |
HUP0501017A2 (en) | Methods and compositions for treatment of central nervous system disorders | |
IL183656A0 (en) | Indenyl derivatives and use thereof for the treatment of neurological disorders | |
IL157145A0 (en) | Use of dc23 antagonists for the treatment of neoplastic disorders | |
IL150289A0 (en) | Drug combination for the treatment of depression and related disorders comprising mirtazapine | |
HK1049122A1 (en) | The use of mirtazapine for the treatment of sleep disorders | |
MXPA03004190A (es) | Tratamiento de trastornos de ansiedad. | |
ZA200505996B (en) | Combination therapy for the treatment of immunoinflammatory disorders | |
IL155817A0 (en) | Combination therapy for estrogen-dependent disorders | |
GB0010496D0 (en) | Treatment of conditions of the central nervous system | |
IL142102A0 (en) | Zinc-sensing receptor and methods of treatment of disorders associated herewith | |
GB0216097D0 (en) | Treatment of proliferative disorders |